AATec Medical Announces its Launch with EUR 2.7 million in Seed Financing to Unlock the Therapeutic Potential of Alpha-1 Antitrypsin
AATec Medical GmbH (AATec), a German biotech company developing a multi-product platform based on recombinant alpha-1 antitrypsin (AAT), today announced that it has commenced operations with seed financing of EUR 2.7 million from private investors, industry experts and family offices. The funds will be used to ...
Source: pharmiweb.com